My Data, My Choice? – German Patient Organizations' Attitudes towards Big Data-Driven Approaches in Personalized Medicine. An Empirical-Ethical Study.

Personalized medicine (PM) operates with biological data to optimize therapy or prevention and to achieve cost reduction. Associated data may consist of large variations of informational subtypes e.g. genetic characteristics and their epigenetic modifications, biomarkers or even individual lifestyle...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Medical Systems Vol. 45; no. 4; pp. 1 - 11
Autores principales: Rauter, Carolin Martina, Wöhlke, Sabine, Schicktanz, Silke
Formato: research tables/charts Journal Article
Publicado: Springer Nature Apr2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149631218&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 149631218
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01485598
        4N0
      jtl: Journal of Medical Systems
      issn: 01485598
      maglogo: N
    pubinfo:
      dt: Apr2021
      vid: 45
      iid: 4
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        149631218
        149631218
        149631218
        10.1007/s10916-020-01702-7
        149631218
      ppf: 1
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: My Data, My Choice? – German Patient Organizations' Attitudes towards Big Data-Driven Approaches in Personalized Medicine. An Empirical-Ethical Study.
      aug:
        au:
          Rauter, Carolin Martina
          Wöhlke, Sabine
          Schicktanz, Silke
        affil: Department of Medical Ethics and History of Medicine, University Medical Center Göttingen, Göttingen, Germany
      sug:
        subj:
          Attitude to Health
          Medical Organizations Germany
          Data Analytics
          Individualized Medicine
          Germany
          Empirical Research
          Human
          World Wide Web
          Morals
          Telephone
          Interviews
          Politics
          Support, Psychosocial
          Decision Making
          Nomenclature
          Qualitative Studies
          Semi-Structured Interview
          Content Analysis
          Data Analysis Software
          Genetic Screening
          Risk Assessment
      ab: Personalized medicine (PM) operates with biological data to optimize therapy or prevention and to achieve cost reduction. Associated data may consist of large variations of informational subtypes e.g. genetic characteristics and their epigenetic modifications, biomarkers or even individual lifestyle factors. Present innovations in the field of information technology have already enabled the procession of increasingly large amounts of such data ('volume') from various sources ('variety') and varying quality in terms of data accuracy ('veracity') to facilitate the generation and analyzation of messy data sets within a short and highly efficient time period ('velocity') to provide insights into previously unknown connections and correlations between different items ('value'). As such developments are characteristics of Big Data approaches, Big Data itself has become an important catchphrase that is closely linked to the emerging foundations and approaches of PM. However, as ethical concerns have been pointed out by experts in the debate already, moral concerns by stakeholders such as patient organizations (POs) need to be reflected in this context as well. We used an empirical-ethical approach including a website-analysis and 27 telephone-interviews for gaining in-depth insight into German POs' perspectives on PM and Big Data. Our results show that not all POs are stakeholders in the same way. Comparing the perspectives and political engagement of the minority of POs that is currently actively involved in research around PM and Big Data-driven research led to four stakeholder sub-classifications: 'mediators' support research projects through facilitating researcher's access to the patient community while simultaneously selecting projects they preferably support while 'cooperators' tend to contribute more directly to research projects by providing and implemeting patient perspectives. 'Financers' provide financial resources. 'Independents' keep control over their collected samples and associated patient-related information with a strong interest in making autonomous decisions about its scientific use. A more detailed terminology for the involvement of POs as stakeholders facilitates the adressing of their aims and goals. Based on our results, the 'independents' subgroup is a promising candidate for future collaborations in scientific research. Additionally, we identified gaps in PO's knowledge about PM and Big Data. Based on these findings, approaches can be developed to increase data and statistical literacy. This way, the full potential of stakeholder involvement of POs can be made accessible in discourses around PM and Big Data.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N